L. Miglianico

发表

EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from “ERBITUX-OUEST”

J. Douillard, N. Padilla, J. Raoul, 2016 .

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial

A. Ravaud, S. Culine, G. Deplanque, 2019, JAMA oncology.

Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.

J. Pignon, T. Conroy, E. Deutsch, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

C. Lepage, J. Taieb, R. Coriat, 2020, European journal of cancer.

Cetuximab (CTX) in first-line treatment of elderly patients with metastatic colorectal cancer (mCRC), KRAS wild type: French multicentre prospective community-based registry and results.

R. Guimbaud, L. Mineur, E. François, 2017 .

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.

J. Pignon, T. Conroy, E. Deutsch, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Effect of combination of a polyamine-free oral nutritional supplement and docetaxel in symptomatic, metastatic castration-resistant prostate cancer patients

J. Moulinoux, X. Artignan, L. Miglianico, 2013 .

Cervico-facial adenoid cystic carcinoma: study of 102 cases. Influence of radiation therapy.

F. Eschwège, P. Wibault, P. Marandas, 1987, International journal of radiation oncology, biology, physics.

A retrospective study of three treatment techniques for T1-T2 base of tongue lesions: surgery plus postoperative radiation, external radiation plus interstitial implantation and external radiation alone.

F. Baillet, M. Housset, D. Martin, 1987, International journal of radiation oncology, biology, physics.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

P. Laurent-Puig, F. Penault-Llorca, C. Borg, 2019, European journal of cancer.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High‐Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI‐PRODIGE Trial

S. Gill, J. Emile, J. Taïeb, 2019, Clinical colorectal cancer.

Breast cancer risk by occupation and industry: analysis of the CECILE study, a population-based case-control study in France.

O. Gaye, P. Guénel, T. Truong, 2011, American journal of industrial medicine.

FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).

C. Borg, O. Bouché, F. Ghiringhelli, 2015 .

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer

R. Guimbaud, P. Soulié, L. Mineur, 2020, PloS one.

Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics

J. Douillard, P. Langlet, E. Jobard, 2014, Oncologie.

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

C. Lepage, J. Taieb, R. Coriat, 2018 .

Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16.

J. Pignon, Y. Bécouarn, J. Bérille, 2011, Journal of Clinical Oncology.

[Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment].

D. Belpomme, P. Desprez, D. Gédouin, 1996, Bulletin du Cancer/Radiothérapie.

Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study.

V. Boige, O. Bouché, L. Mineur, 2021, Journal of Clinical Oncology.

[Pyloric cancer 38 years after surgical repair of hypertrophic pyloric stenosis in infancy. A fortuitous association?].

D. Picot, L. Miglianico, R. Lauvin, 1992, Presse medicale.

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.

J. Pignon, T. Conroy, Y. Bécouarn, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer

V. Boige, O. Bouché, L. Mineur, 2023, JAMA network open.